Equities

Golden Throat Holdings Group Co Ltd

Golden Throat Holdings Group Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)3.75
  • Today's Change0.01 / 0.27%
  • Shares traded42.00k
  • 1 Year change+37.87%
  • Beta0.2042
Data delayed at least 15 minutes, as of Apr 26 2024 08:53 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Golden Throat Holdings Group Company Limited is principally engaged in the manufacture and sales of pharmaceutical, healthcare food and other products. The Company’s flagship product is Golden Throat Lozenges (OTC), which is a type of lozenge mainly designed to relieve symptoms of sore, dry throat and hoarse voice caused by acute pharyngitis. The Company's subsidiaries include Golden Throat Industrial Holdings Limited, Guangxi Golden Throat Investment Consulting Co., Ltd. and Guangxi Golden Throat Co., Ltd..

  • Revenue in HKD (TTM)1.04bn
  • Net income in HKD270.49m
  • Incorporated2014
  • Employees869.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Dawnrays Pharmaceutical (Holdings) Ltd1.24bn352.50m1.76bn1.14k4.990.56873.881.410.23450.23450.82842.060.31562.316.371,088,984.008.859.8911.3612.4954.6056.6928.0327.892.2628.890.040535.33-9.903.94-8.951.4163.922.00
Acotec Scientific Holdings Ltd512.36m15.66m1.96bn638.00120.161.4029.873.830.05210.05211.704.470.31360.72133.44803,074.800.9589--1.03--79.65--3.06--9.122.150.1529--19.80---79.35------
SinoMab Bioscience Ltd1.48m-262.87m2.07bn233.00--6.15--1,405.43-0.2582-0.25820.00150.30880.0015-------26.20-24.62-32.50-27.7230.92---17,810.33-4,451.74---8.150.604------14.45------
Cutia Therapeutics148.81m-2.12bn2.20bn298.00--1.50--14.77-18.27-18.270.72734.80------499,358.40--------51.60---1,426.91--5.38--0.153--1,110.83---253.30------
Abbisko Cayman Ltd20.61m-466.66m2.30bn258.00--1.07--111.76-0.721-0.7210.03183.050.0083--1.4079,880.50-18.74---19.67--100.00---2,264.34------0.0177------12.92------
Cryofocus Medtech Shanghai Co Ltd44.28m-105.41m2.39bn392.00--13.68--53.95-0.4408-0.44080.18520.7302------112,955.00--------75.83---258.23--4.08--0.0597--50.83--13.13------
Laekna Inc0.00-398.79m2.41bn89.00--2.77-----3.30-3.300.002.23------0.00-------------------4.090.0655------52.81------
MicroPort CardioFlow Medtech Corp363.54m-509.86m2.48bn592.00--0.9842--6.84-0.2158-0.21580.15391.050.12052.782.96614,091.40-16.91-17.37-18.11-22.962.06-1.67-140.25-180.829.91-4.090.0293--33.94---3.77------
Peijia Medical Ltd476.98m-424.43m2.49bn1.04k--1.01--5.21-0.625-0.6250.70223.620.14730.77739.51458,634.70-13.11-34.08-14.94-36.9073.7671.62-88.99-448.756.92--0.0886--75.86--3.75------
Frontage Holdings Corp2.03bn84.60m2.61bn1.76k31.270.9717.191.280.04090.04090.98281.320.46360.635.321,156,377.001.914.462.335.2830.1734.004.139.921.394.090.2960.003.7925.61-58.00-0.782640.43--
HighTide Therapeutics Inc0.00-1.02bn2.63bn66.00--3.17-----3.91-3.910.001.61------0.00-------------------0.79740.0229-------393.76------
Golden Throat Holdings Group Co Ltd1.04bn270.49m2.77bn869.0010.251.658.872.670.36590.36591.412.270.41814.821.851,196,221.0010.8811.0015.8515.6372.5772.7926.0224.672.4834.740.2182.96-3.096.73-11.0419.61--38.94
CARsgen Therapeutics Holdings Ltd0.00-808.57m3.14bn516.00--1.61-----1.45-1.450.003.380.00----0.00-29.79---32.14----------9.54--0.0452------16.19------
Biocytogen Pharmaceuticals Beijng Co Ltd775.18m-414.08m3.32bn1.07k--3.90--4.28-1.04-1.041.952.130.273216.215.73727,187.30-14.59---18.88--70.59---53.42--1.24-19.440.4077--34.28--36.38------
CK Life Sciences Intl (Holdings) Inc5.32bn17.25m3.32bn1.93k192.740.791529.250.6230.00180.00180.55380.43590.47282.964.742,755,038.000.15321.110.2111.4330.7630.520.32412.420.85120.87960.586159.000.89360.3407-86.93-42.010.2784--
China Isotope & Radiation Corp7.17bn401.12m3.46bn3.11k8.630.6823.090.48241.251.2522.4315.860.53124.221.792,310,556.006.216.5712.8213.2652.4859.8911.7012.621.73--0.19196.887.8215.35-5.432.88--2.92
Data as of Apr 26 2024. Currency figures normalised to Golden Throat Holdings Group Co Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

0.35%Per cent of shares held by top holders
HolderShares% Held
Dimensional Fund Advisors LPas of 31 Jan 20242.11m0.29%
AXA Investment Managers Asia (Singapore) Ltd.as of 29 Feb 2024406.50k0.06%
Dimensional Fund Advisors Ltd.as of 30 Nov 202338.50k0.01%
DFA Australia Ltd.as of 31 Dec 20239.40k0.00%
More ▼
Data from 31 Dec 2023 - 18 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.